LONDON (Reuters) - The world's most advanced vaccine against dengue fever, being developed by French drugmaker Sanofi SA, proved only 30 percent effective in a large clinical trial in Thailand - far less than hoped. The result leaves uncertain the future of a product that Sanofi has previously said could generate more than 1 billion euros ($1.3 billion) in yearly sales. But researchers said it did show for the first time that a safe vaccine was possible. ...
Get the complete story
No comments:
Post a Comment